NCT00103233已完成3 期
A Randomized Study of Weekly Vinorelbine (Navelbine®) Alone or in Combination With Trastuzumab (Herceptin®) (NSC-688097) for Patients With HER-2-Positive Metastatic Breast Cancer Whose Tumors Have Progressed After Taxane + Trastuzumab Combination Therapy - Phase III
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
研究概览
简要总结
RATIONALE: Drugs used in chemotherapy, such as vinorelbine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as trastuzumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Trastuzumab may also help vinorelbine work better by making tumor cells more sensitive to the drug. Giving vinorelbine together with trastuzumab may be an effective treatment for breast cancer. It is not yet known whether giving vinorelbine together with trastuzumab is more effective than vinorelbine alone in treating breast cancer.
PURPOSE: This randomized phase III trial is studying vinorelbine and trastuzumab to see how well they work compared to vinorelbine alone in treating women with progressive metastatic breast cancer.
详细描述
OBJECTIVES:
- Compare progression-free survival (PFS) of women with HER2-positive progressive metastatic breast cancer treated with vinorelbine with or without trastuzumab (Herceptin®).
- Compare overall survival and time to treatment failure in patients treated with these regimens.
- Compare the toxicity of these regimens in these patients.
- Compare the response rate (complete and partial, confirmed and unconfirmed) in patients with measurable disease treated with these regimens.
- Correlate baseline circulating tumor cells (CTC) with PFS, overall survival, and disease progression status at 9 weeks in patients treated with these regimens.
- Correlate 4-week CTC with subsequent PFS and overall survival of patients treated with these regimens.
OUTLINE: This is a randomized, multicenter study. Patients are randomized to 1 of 2 treatment arms.
- Arm I: Patients receive trastuzumab (Herceptin®) IV over 90 minutes and vinorelbine IV over 10 minutes on day 1 of course 1. Patients receive trastuzumab IV over 30 minutes and vinorelbine IV over 10 minutes on days 1, 8, 15, and 22 in all subsequent courses. If trastuzumab is discontinued due to toxicity, patients may continue to receive vinorelbine alone.
- Arm II: Patients receive vinorelbine IV over 10 minutes on days 1, 8, 15, and 22.
In both arms, courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 主要目的
- Treatment
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •DISEASE CHARACTERISTICS:
- •Histologically confirmed breast cancer
- •Clinical evidence of metastatic disease
- •HER2-positive tumor, as indicated by one of the following methods:
- •HER2 gene amplification by fluorescence in situ hybridization
- •HER2 protein overexpression (3+) by immunohistochemistry
- •Disease progression during or after prior taxane therapy (single-agent paclitaxel, docetaxel, or taxane-containing combination chemotherapy) in combination with trastuzumab (Herceptin®) as first- or second-line chemotherapy for metastatic disease
- •Patients who received maintenance therapy with single-agent trastuzumab after acheiving a response or stable disease to prior taxane/trastuzumab combination therapy are eligible provided disease has progressed
- •Measurable or nonmeasurable disease
- •No effusions or ascites as the only sites of disease
- •No leptomeningeal disease or lymphatic pulmonary metastases
- •Brain metastases allowed provided disease is stable for > 3 months after completion of prior radiotherapy to the brain
- •Hormone receptor status:
- •Not specified
- •PATIENT CHARACTERISTICS:
- •18 and over
- •Menopausal status
- •Not specified
- •Performance status
- •Zubrod 0-1
- •Life expectancy
- •Not specified
- •Hematopoietic
- •Absolute neutrophil count ≥ 1,500/mm^3
- •Platelet count ≥ 100,000/mm^3
- •Hemoglobin ≥ 9 g/dL
- •Bilirubin ≤ 2.0 mg/dL
- •SGOT or SGPT ≤ 2.5 times upper limit of normal (ULN) (< 5 times ULN in the presence of liver metastases)
- •Alkaline phosphatase ≤ 3 times ULN (< 5 times ULN in the presence of liver or bone metastases)
- •Creatinine ≤ 2.0 mg/dL
- •Calcium ≤ 11.0 mg/dL
- •Cardiovascular
- •No history of significant symptomatic cardiac disease
- •LVEF ≥ 50% of the lower limit of normal by MUGA or ECG
- •No pre-existing clinically significant (≥ grade 2) motor or sensory neuropathy except for abnormalities due to cancer
- •No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or adequately treated stage I or II cancer in complete remission
- •Not pregnant or nursing
- •Negative pregnancy test
- •Fertile patients must use effective contraception
- •PRIOR CONCURRENT THERAPY:
- •Biologic therapy
- •See Disease Characteristics
- •At least 28 days since prior trastuzumab
- •No concurrent filgrastim (G-CSF)
- •Chemotherapy
- •See Disease Characteristics
- •No more than 2 prior chemotherapy regimens for metastatic breast cancer
- •Prior adjuvant/neoadjuvant chemotherapy allowed, for a total of 3 prior regimens
- •No prior vinorelbine
- •No other prior chemotherapy after progression on a taxane/trastuzumab regimen
- 另有 9 项未显示
排除标准
- 未提供
研究者
相似试验
已完成
2 期
Vinorelbine in Treating Children With Recurrent or Refractory CancersBrain and Central Nervous System TumorsSarcomaNeuroblastomaNCT00003234Children's Oncology Group50
已完成
1 期
Chemotherapy Plus Trastuzumab in Treating Patients With Breast CancerBreast CancerNCT00014430Dartmouth-Hitchcock Medical Center13
已完成
1 期
Vinorelbine in Treating Patients With Advanced Solid Tumors That Have Not Responded to Treatment and Liver DysfunctionLung CancerUnspecified Adult Solid Tumor, Protocol SpecificNCT00540982City of Hope Medical Center47
已完成
2 期
Vinorelbine and Docetaxel in Treating Women With Metastatic Breast CancerBreast CancerNCT00006682Medstar Health Research Institute
已完成
2 期
S9804: Vinorelbine in Treating Patients With Stage IV MelanomaMelanoma (Skin)NCT00003828SWOG Cancer Research Network24